BMS-955176 manufacturers
- GSK3532795
-
- $1970.00 / 25mg
-
2025-08-21
- CAS:1392312-45-6
- Min. Order:
- Purity:
- Supply Ability: 10g
- GSK3532795
-
- $1970.00 / 25mg
-
2025-07-22
- CAS:1392312-45-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | BMS-955176 Basic information |
| Product Name: | BMS-955176 | | Synonyms: | BMS-955176;BMS-955176
(GSK-3532795;GSK3532795;BMS-955176(free base);GSK-3532795,GSK3532795;Benzoic acid, 4-[17-[[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]amino]-28-norlupa-2,20(29)-dien-3-yl]- | | CAS: | 1392312-45-6 | | MF: | C42H62N2O4S | | MW: | 691.02 | | EINECS: | | | Product Categories: | | | Mol File: | 1392312-45-6.mol |  |
| | BMS-955176 Chemical Properties |
| Boiling point | 780.7±60.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | solubility | DMSO:0.0(Max Conc. mg/mL);0.0(Max Conc. mM) | | pka | 4.36±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | BMS-955176 Usage And Synthesis |
| Uses | GSK3532795 (BMS-955176) is a potent, orally active, second-generation HIV-1 maturation inhibitor, with EC50s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively[1]. | | IC 50 | HIV-1 | | References | [1] Regueiro-Ren A, et al. Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176). J Med Chem. 2018 Aug 23;61(16):7289-7313. DOI:10.1021/acs.jmedchem.8b00854 |
| | BMS-955176 Preparation Products And Raw materials |
|